# EDGAR Filing Document

**Accession Number:** 0001070081
**File Stem:** 0000000000-25-008917
**Filing Date:** 2025-8
**Character Count:** 4306
**Document Hash:** 48e46cf9590f9b019246d776372a1cd2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008917.hdr.sgml**: 20260211

**ACCESSION NUMBER**: 0000000000-25-008917

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250821

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PTC THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001070081
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043416587
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-35969

**BUSINESS ADDRESS:**
- **STREET 1:** 500 WARREN CORPORATE CENTER DRIVE
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059
- **BUSINESS PHONE:** 9082227000

**MAIL ADDRESS:**
- **STREET 1:** 500 WARREN CORPORATE CENTER DRIVE
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PTC THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 19980909
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001070081-25-000012

## Text-Extract

```

                                                             August 21, 2025

Pierre Gravier
Chief Financial Officer
PTC Therapeutics, Inc.
500 Warren Corporate Center Drive
Warren, NJ 07059

        Re: PTC Therapeutics, Inc.
            Form 10-K for Fiscal Year Ended December 31, 2024
            Filed February 27, 2025
            File No. 001-35969
Dear Pierre Gravier:

       We have reviewed your filing and have the following comments.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-K for Fiscal Year Ended December 31, 2024
Item 1. Business
Our Collaborations, License Agreements and Funding Arrangements
National Taiwan University, page 24

1.     Please revise in subsequent filings to disclose the sales royalty
percentage to a range
       within 10 percentage points pursuant to the NTU Licensing Agreement.
Shiratori, page 26

2.     Please revise future filings to disclose the total aggregate amount of
milestone
       payments made to date and may be paid in the future pursuant to the
Shiratori License
       Agreement.
Intellectual Property
Patents and trade secrets, page 28

3.     We note your disclosure on page 29 that composition of matter patents
related to
       ataluren expired in 2024 and its patents related to therapeutic methods
are set to expire
 August 21, 2025
Page 2

       in 2026 and 2027. We also note your disclosure on page 30 that patents
related to
       vaquinone will begin expiring in 2026. In future filings, please expand
your risk factor
       disclosure to discuss specific risks that may result based on ataluren
and vaquinone   s
       imminent patent expirations.
Management's Discussion and Analysis of Financial Condition and Results of
Operations
Financial operations overview
Research and development expense, page 122

4.     You disclose that you track expenses related to your clinical programs
and certain
       preclinical programs on a per project basis. Please provide revised
disclosure to be
       included in future filings to break out the 'Development' line item by
program.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

        Please contact Christine Torney at 202-551-3652 or Vanessa Robertson at
202-551-
3649 if you have questions regarding comments on the financial statements and
related
matters. Please contact Daniel Crawford at 202-551-7767 or Chris Edwards at
202-551-6761
with any other questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._